Trial
NCT03556202
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Psoriasis
Intervention
Mirikizumab
Why stopped
The study was terminated due to a strategic business decision made by the Sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-21